Spotlight
Partners
- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Now there's an echinocandin antifungal to treat kids
Cancidas, previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years.
Merck's Cancidas (caspofungin acetate), previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years. The Whitehouse Station, N.J., firm claims that the approval makes Cancidas the first and only echinocandin therapy approved domestically for the treatment of children with indicated fungal infections. The new expanded labeling is based on data from five clinical trials involving 171 pediatric patients.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Related Videos
Related Content
